On the public citation graph

Pioneering government-sponsored drug repositioning collaborations: progress and learning

0 signed · 64 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/ana.24394openalex-snapshot
F yn inhibition rescues established memory and synapse loss in A lzheimer mice
inferredcites →https://doi.org/10.1016/j.drudis.2012.11.005openalex-snapshot
Challenges and recommendations for obtaining chemical structures of industry-provided repurposing candidates
inferredcites →https://doi.org/10.1038/nrd1468openalex-snapshot
Drug repositioning: identifying and developing new uses for existing drugs
inferredcites →https://doi.org/10.1038/nrd3461openalex-snapshot
Mining for therapeutic gold
inferredcites →https://doi.org/10.1038/nrd3473openalex-snapshot
Could pharma open its drug freezers?
inferredcites →https://doi.org/10.1038/nrd4309openalex-snapshot
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
inferredcites →https://doi.org/10.1089/adt.2015.29006.cmcdrrropenalex-snapshot
The NIH-Industry New Therapeutic Uses Pilot Program: Demonstrating the Power of Crowdsourcing

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.1002/prp2.510openalex-snapshot
Compound asset sharing initiatives between pharmaceutical companies, funding bodies, and academia: Learnings and successes
inferred← citeshttps://doi.org/10.1007/164_2019_334openalex-snapshot
Perspectives of Pharmacology over the Past 100 Years
inferred← citeshttps://doi.org/10.1007/978-3-319-67144-4_14openalex-snapshot
New Therapeutic Uses for Existing Drugs
inferred← citeshttps://doi.org/10.1007/s11224-019-01414-wopenalex-snapshot
Diarylthiazole and diarylimidazole selective COX-1 inhibitor analysis through pharmacophore modeling, virtual screening, and DFT-based approaches
inferred← citeshttps://doi.org/10.1016/b978-0-12-816125-8.00019-5openalex-snapshot
In Silico Modeling of FDA-Approved Drugs for Discovery of Anti-Cancer Agents: A Drug-Repurposing Approach
inferred← citeshttps://doi.org/10.1016/b978-0-12-819668-7.00001-4openalex-snapshot
Drug repurposing for cancer therapy—an introduction
inferred← citeshttps://doi.org/10.1016/b978-0-12-820472-6.00116-xopenalex-snapshot
Magic bullets: Drug repositioning and drug combinations
inferred← citeshttps://doi.org/10.1016/j.coisb.2017.04.010openalex-snapshot
Drug repositioning beyond the low-hanging fruits
inferred← citeshttps://doi.org/10.1016/j.csbj.2021.08.003openalex-snapshot
A data-driven methodology towards evaluating the potential of drug repurposing hypotheses
inferred← citeshttps://doi.org/10.1016/j.drudis.2017.10.009openalex-snapshot
Computational drug repositioning for rare diseases in the era of precision medicine
inferred← citeshttps://doi.org/10.1016/j.semcancer.2019.10.018openalex-snapshot
Current state and future perspective of drug repurposing in malignant glioma
inferred← citeshttps://doi.org/10.1017/9781009746274.015openalex-snapshot
Paying for medicines
inferred← citeshttps://doi.org/10.1038/nrd.2018.168openalex-snapshot
Drug repurposing: progress, challenges and recommendations
inferred← citeshttps://doi.org/10.1038/s41467-025-56690-4openalex-snapshot
Drug repurposing for Alzheimer’s disease and other neurodegenerative disorders
inferred← citeshttps://doi.org/10.1038/s41581-024-00864-8openalex-snapshot
Drug repurposing for glomerular diseases: an underutilized resource
inferred← citeshttps://doi.org/10.1038/s41598-017-01438-4openalex-snapshot
Importance of the novel organic cation transporter 1 for tyrosine kinase inhibition by saracatinib in rheumatoid arthritis synovial fibroblasts
inferred← citeshttps://doi.org/10.1038/s41598-017-04233-3openalex-snapshot
Drug-Repositioning Screening for Keap1-Nrf2 Binding Inhibitors using Fluorescence Correlation Spectroscopy
inferred← citeshttps://doi.org/10.1039/9781839163401openalex-snapshot
Drug Repurposing
inferred← citeshttps://doi.org/10.1039/9781839163401-00001openalex-snapshot
Introduction and Historical Overview of Drug Repurposing Opportunities
inferred← citeshttps://doi.org/10.1039/9781839163401-00052openalex-snapshot
Role of Industry
inferred← citeshttps://doi.org/10.1039/c6md00129gopenalex-snapshot
The evolution of drug discovery: from phenotypes to targets, and back
inferred← citeshttps://doi.org/10.1055/a-1971-6965openalex-snapshot
Repurposing of Drugs for Cardiometabolic Disorders: An Out and Out Cumulation
inferred← citeshttps://doi.org/10.1080/17460441.2025.2474661openalex-snapshot
Drug repurposing in amyotrophic lateral sclerosis (ALS)
inferred← citeshttps://doi.org/10.1080/2162402x.2016.1149674openalex-snapshot
Trial Watch—Small molecules targeting the immunological tumor microenvironment for cancer therapy
inferred← citeshttps://doi.org/10.1093/noajnl/vdaa145openalex-snapshot
Adult precision medicine: learning from the past to enhance the future
inferred← citeshttps://doi.org/10.1101/228171openalex-snapshot
In silico and in vitro screening of FDA-approved drugs for potential repurposing against tuberculosis
inferred← citeshttps://doi.org/10.1109/rivf.2016.7800298openalex-snapshot
Detection of new drug indications from electronic medical records
inferred← citeshttps://doi.org/10.1111/bcp.14964openalex-snapshot
Repurposing existing therapeutics, its importance in oncology drug development: Kinases as a potential target
inferred← citeshttps://doi.org/10.1111/bph.13895openalex-snapshot
Drug repurposing screens and synergistic drug‐combinations for infectious diseases
inferred← citeshttps://doi.org/10.1111/cts.13293openalex-snapshot
A public–private collaboration model for clinical innovation
inferred← citeshttps://doi.org/10.1172/jci.insight.95042openalex-snapshot
Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva
inferred← citeshttps://doi.org/10.1177/0269881116653109openalex-snapshot
Gene-set analysis based on the pharmacological profiles of drugs to identify repurposing opportunities in schizophrenia
inferred← citeshttps://doi.org/10.1177/1091581817709773openalex-snapshot
Why Do Promising Therapies Stall in Development and How Can We Move Them Forward?
inferred← citeshttps://doi.org/10.1177/2168479018811829openalex-snapshot
Entry Into New Therapeutic Areas: The Effect of Alliance on Clinical Trials
inferred← citeshttps://doi.org/10.1186/s12891-022-05471-xopenalex-snapshot
Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPFOP)
inferred← citeshttps://doi.org/10.1186/s12913-022-08272-zopenalex-snapshot
Drug repurposing: a systematic review on root causes, barriers and facilitators
inferred← citeshttps://doi.org/10.1186/s13063-021-05273-xopenalex-snapshot
Exploring new uses for existing drugs: innovative mechanisms to fund independent clinical research
inferred← citeshttps://doi.org/10.21203/rs.3.rs-1191760/v1openalex-snapshot
Why promising drugs are shelved and barriers and facilitators to their re-purposing: A systematic literature review
inferred← citeshttps://doi.org/10.21203/rs.3.rs-26065/v1openalex-snapshot
New Mechanisms to Fund Independent Clinical Trials for Repurposing Off-Patent or Generic Medicines
inferred← citeshttps://doi.org/10.2174/0125899775327220240822111611openalex-snapshot
Exploring Novel Therapeutic Avenues: Drug Repurposing for Neurodegenerative Movement Disorders
inferred← citeshttps://doi.org/10.2174/2589977513666210211163711openalex-snapshot
Drug Repurposing: An Emerging Tool for Drug Reuse, Recycling and Discovery
inferred← citeshttps://doi.org/10.2217/pgs-2016-0062openalex-snapshot
The Neuroimmune Transcriptome and Alcohol Dependence: Potential for Targeted Therapies
inferred← citeshttps://doi.org/10.3389/fmed.2021.817663openalex-snapshot
Repurposing of Medicines in the EU: Launch of a Pilot Framework
inferred← citeshttps://doi.org/10.3389/fphar.2022.960701openalex-snapshot
How to balance valuable innovation with affordable access to medicines in Belgium?
inferred← citeshttps://doi.org/10.3389/fphar.2022.974849openalex-snapshot
Drug repositioning: A bibliometric analysis
inferred← citeshttps://doi.org/10.3389/fphar.2025.1670845openalex-snapshot
Overcoming barriers to off-patent drug repurposing: a lifecycle-based policy solutions
inferred← citeshttps://doi.org/10.3390/biomedicines9020213openalex-snapshot
Challenges and Opportunities for Drug Repositioning in Fibrodysplasia Ossificans Progressiva
inferred← citeshttps://doi.org/10.3390/ijms24032101openalex-snapshot
The Role of Organic Cation Transporters in the Pharmacokinetics, Pharmacodynamics and Drug–Drug Interactions of Tyrosine Kinase Inhibitors
inferred← citeshttps://doi.org/10.4155/fmc-2016-0123openalex-snapshot
Challenges in the Development of Novel Anticryptococcal Agents
inferred← citeshttps://doi.org/10.5863/1551-6776-21.1.4openalex-snapshot
The Rescue and Repurposing of Pharmaceuticals: Augmenting the Drug Development Paradigm
inferred← citeshttps://doi.org/10.6026/97320630012368openalex-snapshot
Docking-based virtual screening of known drugs against murE of Mycobacterium tuberculosis towards repurposing for TB
inferred← citeshttps://doi.org/10.6084/m9.figshare.14538717openalex-snapshot
Additional file 1 of Exploring new uses for existing drugs: innovative mechanisms to fund independent clinical research
inferred← citeshttps://doi.org/10.6084/m9.figshare.14538720openalex-snapshot
Additional file 2 of Exploring new uses for existing drugs: innovative mechanisms to fund independent clinical research
inferred← citeshttps://doi.org/10.6084/m9.figshare.19959934openalex-snapshot
Additional file 1 of Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPFOP)
inferred← citeshttps://doi.org/10.6084/m9.figshare.19959937openalex-snapshot
Additional file 2 of Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPFOP)
inferred← citeshttps://doi.org/10.6084/m9.figshare.20408446openalex-snapshot
Additional file 1 of Drug repurposing: a systematic review on root causes, barriers and facilitators
inferred← citeshttps://doi.org/10.70675/63ceaea1ze673z40c3z9960zed4c40d88ea9openalex-snapshot
Validation de nouvelles cibles thérapeutiques dans le glioblastome par une approche de pharmacologie fonctionnelle
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.